Wedbush Maintains Outperform on Immunome, Raises Price Target to $35
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.